Kolexia
Rolland Frederic Oncologie médicale
Rolland Frederic
Oncologie médicale
Institut de cancérologie de l'Ouest
Saint-Herblain, France
210 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Néphrocarcinome Carcinome épidermoïde Tumeurs du rein Tumeurs de la prostate Carcinome épidermoïde de la tête et du cou Tumeurs de la tête et du cou Métastase tumorale Tumeurs de la vessie urinaire

Collaborateurs

Voir plus
Gravis-Mescam Gwenaelle
Gravis-Mescam Gwenaelle
Centre Paoli-Calmettes, Marseille, France
Laguerre Brigitte
Laguerre Brigitte
Centre Eugène Marquis, Rennes, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France
Geoffrois Lionnel
Geoffrois Lionnel
Institut de cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France

Industries

Voir plus
Pfizer
9 collaboration(s)
Dernière en 2023
BMS
8 collaboration(s)
Dernière en 2021
MSD
8 collaboration(s)
Dernière en 2023
Ipsen
5 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
BISCAY: An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).
Essai Clinique (AstraZeneca)   11 mars 2024
AdCC_2023-01: A Phase Ib Study of OBT076 or OBT076 Followed by Balstilimab in Patients With Recurrent or Metastatic (R/M) Adenoid Cystic Carcinoma (AdCC) of the Head and Neck (H&N)
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   06 mars 2024
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
COTESARC: A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
Essai Clinique (Centre Léon-Bérard)   09 février 2024
A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley): A Phase II, Multicenter, Randomized, Open Label, Parallel-Arm, Umbrella Study of Avelumab (MSB0010718C) in Combination With Other AntiTumor Agents as a Maintenance Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma Whose Disease Did Not Progress With First Line Platinum-Containing Chemotherapy (JAVELIN Bladder Medley)
Essai Clinique (Emd Serono)   05 février 2024
Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: Analysis of the NIVOREN GETUG-AFU 26 study.
European journal of cancer (Oxford, England : 1990)   03 février 2024
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors: A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors
Essai Clinique (Unicancer)   01 février 2024
EDEN: Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm Seminomas
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
PAXIPEM: Multicenter Phase II Study of Axitinib +/- Pembrolizumab in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)
Essai Clinique (Centre Léon-Bérard)   24 janvier 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.
Oncoimmunology   20 décembre 2023